Benzinga | Jul 8, 2021 09:28AM EDT

Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia

* Vor Biopharma Inc (NASDAQ:VOR) has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ).

* Under the terms of the collaboration, Vor Biopharma will investigate the combination of Vor's engineered hematopoietic stem cell (eHSC) platform with one of Janssen's bi-specific antibodies for acute myeloid leukemia (AML).

* The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.

* Price Action: VOR shares closed at $18.15 on Wednesday.